Search research articles
Contact Us
Filters
Showing results (21-30 of 42) with videos related to
Page
of 5
Sort By:
La Revue De Medecine Interne
|
April 1, 2019
[A tool for knowledge transfer in internal medicine from Quebec: "BaladoCritique: Journal Club" podcast]
L Lanthier, M-É Plourde, G Huard, et al.
La Revue De Medecine Interne
|
November 3, 2021
[For patients with heart failure with preserved ejection fraction, is empagliflozine effective and safe for preventing cardiovascular mortality and heart failure hospitalization?]
L Lanthier, C Dussault, M-É Plourde, et al.
La Revue De Medecine Interne
|
May 16, 2024
[Among patients with metabolic dysfunction associated steatohepatitis (MASH), is resmetirom 80 or 100mg superior to placebo in reversing MASH and/or fibrosis on liver biopsy, and is it safe?]
L Lanthier, D Grbic, M-É Plourde, et al.
La Revue De Medecine Interne
|
December 14, 2020
[In patients with moderate chronic kidney disease with albuminuria, including non-diabetic patients, does dapagliflozin provide renal and cardiovascular benefit compared to placebo?]
L Lanthier, M Masse, M-É Plourde, et al.
La Revue De Medecine Interne
|
May 14, 2023
[In adults admitted to the intensive care unit for severe community-acquired pneumonia, does adding hydrocortisone to standard treatment reduce 28-days mortality compared to placebo, and is it safe?]
L Lanthier, M Mayette, M-É Plourde, et al.
La Revue De Medecine Interne
|
April 12, 2023
[In patients with moderate chronic kidney disease, including non-diabetic patients, does empagliflozin provide renal and cardiovascular benefit compared to placebo, and is it safe?]
L Lanthier, A Viau-Trudel, M-E Plourde, et al.
La Revue De Medecine Interne
|
January 16, 2024
[Among adults with cardiovascular disease and BMI≥27kg/m<sup>2</sup> but no diabetes, does semaglutide lower risk of cardiovascular mortality, myocardial infarction, or stroke when compared with placebo, and is it safe?]
L Lanthier, M-F Langlois, M-É Plourde, et al.
Journal of Evaluation in Clinical Practice
|
June 7, 2016
Thromboprophylaxis adherence to the ninth edition of American college of chest physicians antithrombotic guidelines in a tertiary care centre: a cross-sectional study
T Thériault, M Touchette, V Goupil, et al.
La Revue De Medecine Interne
|
April 11, 2021
[For obese patients or for patients who are overweight and have an associated comorbidity, how safe and effective is semaglutide as compared with placebo as an adjunct to lifestyle intervention for reducing body weight and other related end points?]
L Lanthier, M-F Langlois, M-É Plourde, et al.
La Revue De Medecine Interne
|
October 20, 2020
[In patients hospitalized for COVID-19, does dexamethasone reduce 28-days mortality compared to standard treatment?]
L Lanthier, M Mayette, G Huard, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 42) with videos related to
Sort By:
Page
of 5
La Revue De Medecine Interne
|
April 1, 2019
[A tool for knowledge transfer in internal medicine from Quebec: "BaladoCritique: Journal Club" podcast]
L Lanthier, M-É Plourde, G Huard, et al.
La Revue De Medecine Interne
|
November 3, 2021
[For patients with heart failure with preserved ejection fraction, is empagliflozine effective and safe for preventing cardiovascular mortality and heart failure hospitalization?]
L Lanthier, C Dussault, M-É Plourde, et al.
La Revue De Medecine Interne
|
May 16, 2024
[Among patients with metabolic dysfunction associated steatohepatitis (MASH), is resmetirom 80 or 100mg superior to placebo in reversing MASH and/or fibrosis on liver biopsy, and is it safe?]
L Lanthier, D Grbic, M-É Plourde, et al.
La Revue De Medecine Interne
|
December 14, 2020
[In patients with moderate chronic kidney disease with albuminuria, including non-diabetic patients, does dapagliflozin provide renal and cardiovascular benefit compared to placebo?]
L Lanthier, M Masse, M-É Plourde, et al.
La Revue De Medecine Interne
|
May 14, 2023
[In adults admitted to the intensive care unit for severe community-acquired pneumonia, does adding hydrocortisone to standard treatment reduce 28-days mortality compared to placebo, and is it safe?]
L Lanthier, M Mayette, M-É Plourde, et al.
La Revue De Medecine Interne
|
April 12, 2023
[In patients with moderate chronic kidney disease, including non-diabetic patients, does empagliflozin provide renal and cardiovascular benefit compared to placebo, and is it safe?]
L Lanthier, A Viau-Trudel, M-E Plourde, et al.
La Revue De Medecine Interne
|
January 16, 2024
[Among adults with cardiovascular disease and BMI≥27kg/m<sup>2</sup> but no diabetes, does semaglutide lower risk of cardiovascular mortality, myocardial infarction, or stroke when compared with placebo, and is it safe?]
L Lanthier, M-F Langlois, M-É Plourde, et al.
Journal of Evaluation in Clinical Practice
|
June 7, 2016
Thromboprophylaxis adherence to the ninth edition of American college of chest physicians antithrombotic guidelines in a tertiary care centre: a cross-sectional study
T Thériault, M Touchette, V Goupil, et al.
La Revue De Medecine Interne
|
April 11, 2021
[For obese patients or for patients who are overweight and have an associated comorbidity, how safe and effective is semaglutide as compared with placebo as an adjunct to lifestyle intervention for reducing body weight and other related end points?]
L Lanthier, M-F Langlois, M-É Plourde, et al.
La Revue De Medecine Interne
|
October 20, 2020
[In patients hospitalized for COVID-19, does dexamethasone reduce 28-days mortality compared to standard treatment?]
L Lanthier, M Mayette, G Huard, et al.
Page
of 5